AZA Combined With RCHOP in P53-mutated DLBCL.

This study is testing whether adding azacitidine (AZA), a drug that affects how genes are switched on and off, to the standard R-CHOP chemotherapy regimen improves outcomes in patients with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that has a TP53 gene mutation. **You may be eligible if...** - You are between 18 and 70 years old - You have been newly diagnosed with DLBCL that has a TP53 gene mutation - You have not previously received treatment for this lymphoma - Your heart function is adequate (LVEF above 45%) - Your liver, kidney, and blood counts meet the required levels **You may NOT be eligible if...** - You have already received treatment for DLBCL - Your DLBCL does not have a TP53 mutation - You are outside the age range of 18 to 70 - You have significant liver, heart, or kidney problems Talk to your doctor to see if this trial is right for you.